Phase III Results Could Boost Pfizer Revenue Ahead Of Xtandi’s Exclusivity Loss
Pfizer and Astellas announced positive topline Phase III results in non-metastatic prostate cancer for Xtandi, one of the top-selling drugs in Pfizer’s portfolio set to lose patent exclusivity this decade.
You may also be interested in...
Data from the Phase III EMBARK study showed a significant improvement for the drug both in combination with leuprolide and as a monotherapy in reducing risk of metastasis or death in nmHSPC.
Seagen’s pipeline includes 11 new molecular entities and would double Pfizer’s early-stage oncology clinical pipeline. A next-generation cytotoxic payload for ADCs is on the way too.
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.